Daré Bioscience Croissance future

Future contrôle des critères 5/6

Daré Bioscience devrait augmenter ses bénéfices et ses revenus de 71.4% et de 78.4% par an respectivement, tandis que le BPA devrait croître de croître de 65.1% par an.

Informations clés

71.4%

Taux de croissance des bénéfices

65.1%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.8%
Taux de croissance des recettes	78.4%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22

Dare Bioscience EPS misses by $0.06

Nov 12

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:DARE - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	21	-21	N/A	N/A	2
12/31/2025	2	-20	N/A	N/A	4
12/31/2024	1	-3	N/A	N/A	4
9/30/2024	2	-4	-9	-8	N/A
6/30/2024	3	-7	-11	-10	N/A
3/31/2024	3	-29	-30	-30	N/A
12/31/2023	3	-30	-39	-39	N/A
9/30/2023	1	-41	-37	-37	N/A
6/30/2023	N/A	-40	-20	-20	N/A
3/31/2023	10	-31	-22	-22	N/A
12/31/2022	10	-31	-18	-18	N/A
9/30/2022	10	-25	-22	-22	N/A
6/30/2022	10	-30	-29	-29	N/A
3/31/2022	N/A	-40	-33	-33	N/A
12/31/2021	N/A	-39	-29	-29	N/A
9/30/2021	N/A	-38	-28	-28	N/A
6/30/2021	N/A	-33	-35	-35	N/A
3/31/2021	N/A	-30	-27	-27	N/A
12/31/2020	N/A	-27	-25	-25	N/A
9/30/2020	N/A	-23	-20	-20	N/A
6/30/2020	N/A	-19	-18	-18	N/A
3/31/2020	N/A	-16	-17	-17	N/A
12/31/2019	N/A	-15	-13	-13	N/A
9/30/2019	N/A	-14	-12	-12	N/A
6/30/2019	N/A	-13	-12	-12	N/A
3/31/2019	N/A	-12	-12	-11	N/A
12/31/2018	N/A	-17	-11	-10	N/A
9/30/2018	N/A	-23	-9	-9	N/A
6/30/2018	N/A	-22	N/A	-7	N/A
3/31/2018	N/A	-19	N/A	-5	N/A
12/31/2017	N/A	-12	N/A	-3	N/A
9/30/2017	N/A	-3	N/A	-2	N/A
6/30/2017	N/A	-1	N/A	0	N/A
3/31/2017	N/A	-1	N/A	0	N/A
12/31/2016	N/A	-1	N/A	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: DARE devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: DARE devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: DARE devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de DARE ( 78.4% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de DARE ( 78.4% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de DARE devrait être élevé dans 3 ans

Daré Bioscience Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 11% to US$5.33

Consensus revenue estimates decrease by 18%

Consensus revenue estimates increase by 29%, EPS downgraded

No longer forecast to breakeven

Price target increased by 13% to US$6.00

Forecast to breakeven in 2025

Recent updates

Daré Bioscience, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million.

Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024

Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer

Daré Bioscience, Inc. Announces Executive Changes

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study

Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1

Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

New major risk - Revenue and earnings growth

We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

Daré Bioscience, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Price target decreased by 11% to US$5.33

New major risk - Financial position

New major risk - Revenue size

Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Daré Bioscience Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women

New minor risk - Profitability

Consensus revenue estimates decrease by 18%

Daré Bioscience, Inc. Provides Update on Activities to Support Commercial Launch of XACIATO

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Dare Bioscience, Inc. Announces Positive Topline Data from the Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Consensus revenue estimates increase by 29%, EPS downgraded

No longer forecast to breakeven

Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Price target increased by 13% to US$6.00

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

Daré Bioscience, Inc. Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study

Forecast to breakeven in 2025

Daré Bioscience Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates fall by 38%

Consensus forecasts updated

Price target decreased to US$5.33

Daré Bioscience, Inc. Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

Daré Bioscience Announces Subject Screening for Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Daré Announces Topline Results of Its Phase 1/2 Clinical Study of Dare-HRT1

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Daré Bioscience, Inc. Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Daré Bioscience Announces Interim Analysis of Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Consensus revenue estimates increase by 24%

No longer forecast to breakeven

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Daré Bioscience, Inc., Annual General Meeting, Jul 14, 2022

Consensus revenue estimates increase by 11%

Daré Bioscience, Inc., Annual General Meeting, Jun 23, 2022

Price target increased to US$8.25

Forecast to breakeven in 2024

Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-HRT1

Consensus revenue estimates increase by 43%

Forecast to breakeven in 2024

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Price target increased to US$8.25

No longer forecast to breakeven

Diving Back Into Daré Bioscience Again

Forecast to breakeven in 2024

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Daré Bioscience, Inc. Announces NIH Grant Award to Support Development of DARE-LARC1